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OBJECTIVES: To determine the relevance of 
nasal carriage of Staphylococcus aureus, either 
methicillin-sensitive (MSSA) or methicillin- 
resistant (MRSA), as a risk factor for the 
development of nosocomial S aureus 
bacteremia during an MRSA outbreak. 
PATIENTS AND METHODS: In this prospective 
cohort study, 488 patients admitted to an 
intensive care unit (ICU) during a l-year period 
were screened with nasal swabs within 48 hours 
of admission and weekly thereafter in order to 
identify nasal S aureus carriage. Nasal 
staphylococcal carriers were observed until 
development of S aureus bacteremia, ICU 
discharge, or death. 
RESULTS: One hundred forty-seven (30.1%) of 
488 patients were nasal S aureus carriers: 84 
patients (17.2%) harbored methicillin-sensitive 
S aureus; and 63 patients (12.9%) methicillin- 
resistant S aureus. Nosocomial S aureus 
bacteremia was diagnosed in 38 (7.7%) of 488 
patients. Rates of bacteremia were 24 (38%) of 
the MRSA carriers, eight (9.5%) of the MSSA 
carriers, and six (1.7%) of noncarriers. After 
adjusting for other predictors of bacteremia by 
means of a Cox proportional hazard regression 
model, the relative risk for S aureus bacteremia 
was 3.9 (95% confidence interval, 1.6-9.8; P = 
0.002) for MRSA carriers compared with MSSA 
carriers. 
CONCLUSIONS: Among ICU patients, nasal 
carriers of S aureus are at higher risk for S 
aureus bacteremia than are noncarriers; in the 
setting of an MRSA outbreak, colonization by 
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methicillin-resistant strains represents a greater 
risk than does colonization by MSSA and 
strongly predicts the occurrence of MRSA 
bacteremia. Am J Med. 1996;100:509-a516. 
lthough Staphylococcus aureus has maintained Al ‘ts role as one of the most common nosocomial 
pathogens since the 195Os, a renewed interest in no- 
socomial staphylococcal infections has emerged in 
recent years, since methicillin-resistant S aureus 
(MRSA) has been reported with increasing fre- 
quency worldwide.‘-” In large tertiary hospitals, out- 
breaks of MRSA are commonly encountered in crit- 
ical care areas,” where colonized and infected 
patients constitute a significant reservoir and a 
source of spreading to other hospitalized patients. 
During these outbreaks, MRSA does not simply re- 
place methicillin-sensitive strains but iseems to 
emerge as a distinct microorganism, increasing the 
overall number of staphylococcal infections6 During 
the outbreak of MRSA infections detected at our in- 
stitution at the end of 1989, we observed a high in- 
cidence of MRSA bacteremia among nasal S aureus 
carriers admitted to the intensive care unit (ICU) 
with nasal staphylococcal carriage, while the inci- 
dence of nosocomial bacteremia due to methicillin- 
sensitive strains has remained unchanged.7 Stable 
nasal staphylococcal carriage has been considered 
to play an important role in the pathogenesis of sur- 
gical staphylococcal wound infections, ‘-lo as well as 
in patients on hemodialysis with S aureus bactere- 
mia.ll-1” However, its role in the subsequent devel- 
opment of nosocomial bloodstream infections in 
critically ill patients admitted to the IC’U, where 
cross infections may be frequent, is uncertain. 
We therefore undertook a prospective study 
among ICU patients to evaluate the relevance of na- 
sal carriage of S aweus, either methicillin-sensitive 
or methicillin-resistant, as a risk factor for the de- 
velopment of nosocomial S aureus bacteremia in the 
setting of an MRSA outbreak. 
PATIENTS AND METHODS 
The study was carried out in the Hospital de Be- 
llvitge, a l,OOO-bed teaching hospital for adult pa- 
tients in Barcelona. Our hospital has three medical- 
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surgical ICUs with a total of 36 beds, and an annual 
admittance rate of 600-700 patients. 
Infection Control Policy 
Nosocomial infection surveillance has been car- 
ried out in our hospital over the past 15 years. All 
patients with bacteremia identified daily at our mi- 
crobiology laboratory are visited by an infectious 
disease physician who fills out a computer-assisted 
protocol and provides medical advice when indi- 
cated. 
The MRSA Infection Control Program was intro- 
duced in 1990, when the initial MRSA isolates were 
detected, as has previously been reported.7 The 
MRSA patients were daily identified by laboratory 
surveillance. The control measures applied were as 
described below. 
In surgical and medical wards the program in- 
cludes identification and isolation of all patients with 
MRSA colonization or infection, use of nasal mupi- 
rocine for nasal carriers among health care workers 
and colonized patients, l4 reinforcement of careful 
handwashing, and educational programs. In the ICU 
the program includes screening of patients with na- 
sal swabs for early MRSA detection and isolation 
purposes. Treatment with nasal mupirocine oint- 
ment was not considered for MRSA-colonized pa- 
tients due to the potential risk of developing mupi- 
rocine resistance among critically ill patients with 
nasogastric tubes, endotracheal intubation, or tra- 
cheostomy.‘4,15 Health-care workers colonized with 
MRSA were treated with a 5-day course of intranasal 
mupirocine as has been recommended.14 Treatment 
with nasal mupirocine was not administrated to pa- 
tients or health-care workers colonized with MSSA 
strains. 
Patients and Definitions 
All patients admitted to ICUs from March 1991 to 
April 1992 for more than 48 hours were included in 
the study. Patients were weekly screened with nasal 
swabs in order to identify nasal staphylococcal car- 
riage. Blood cultures were performed when bacter- 
emia was suspected by the attending physician. All 
nasal staphylococcal carriers were prospectively 
surveyed until progression to one of the following 
situations: S aureus bacteremia, ICU discharge, or 
death. Significant clinical and epidemiological fea- 
tures of all nasal carriers occurring during their stay 
in the ICU were included in a computer-assisted pro- 
tocol. 
Nasal staphylococcal carriage was defined as the 
presence of S aureus in nares culture at any period 
during ICU hospitalization. Patients with transient 
carriage or low level carriers (one or more negative 
cultures after initial positive detection) were also 
considered staphylococcal colonized patients. 
Patients were considered to have S aureus bac- 
teremia when one or more blood cultures were pos- 
itive for S aureus in a clinical setting of infection. 
The episode of bacteremia was considered acquired 
in the ICU if it appeared 72 hours after admission to 
this area and no evidence of staphylococcal infection 
was present at admission. 
Primary bacteremia was defined according to CDC 
criteria l8 as those episodes of bacteremia of un- 
known source and those with bacteremia due to in- 
travascular catheter infection. Secondary bacter- 
emia was considered when a portal of en.try was clin- 
ically evident. Length of nasal S aureus carriage was 
defined as the number of days of nasal staphylococ- 
cal carriage from the day of the first nasal swab pos- 
itive for S aweus to the day of S aureus bacteremia, 
ICU discharge, or death. 
Underlying diseases were classified into three 
groups according to the McCabe classification: I6 
group 1 includes chronic or curable disease; group 2 
includes malignancy or any other disease with a life 
expectancy of less than 5 years; and group 3 includes 
diseases with life expectancy of less than 1 year. Se- 
verity of illness was calculated by means of evalua- 
tion of the Simplified Acute Physiol!ogic Score 
(=I-1 I7 measured at ICU admission and also mea- 
sured on the day of detection of nasal colonization. 
Antibiotic therapy was considered when the pa- 
tient received one or more antimicrobial agents for 
more than 48 hours during the ICU stay. Antibiotic 
therapy was divided into two periods: those admin- 
istered during ICU stay before the day that staphy- 
lococcal colonization was detected and those re- 
ceived after staphylococcal colonization and up to 
bacteremia, discharge, or death. Intravascular cath- 
eterization, urinary catheter, mechanical ventilation, 
or tracheostomy were considered if they were in 
place for more than 48 hours during the ICU stay. 
Microbiological Studies and Molecular Typing 
Screening swabs collected from the anterior nares 
of ICU patients submitted to the laboratory for 
MRSA screening were inoculated onto mannitol-salt 
agar plates. All cultures were incubated at 35°C for 
2 days and examined daily for evidence of growth. 
Blood cultures were performed by inoculating 5- 10 
mL of blood into a commercial two-bottle system 
(BACTEC system; Becton Dickinson, Diagnostic In- 
strument System, Sparks, MI). Gram-positive, cata- 
lase-positive cocci were identified as S ar&rem in ac- 
cordance with their growth characteristics on 
mannitol-salt agar, DNA hydrolysis, latex agglutina- 
tion (Slidex StaphKit; Biomerieux, Prance) and the 
coagulase reaction. Susceptibility of oxacillin was 
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tested by disk diffusion using a 1-bg oxacillin disk 
and standard zone size criteria.” The minimum in- 
hibitory concentration (MIC) was determined in a 
representative sample of MRSA strains by commer- 
cial plates (Pos Combo Panel 41, MicroScan R, West 
Sacramento, CA), with two oxacillin dilutions wells 
of 1 and 2 pg/mL, supplemented with 2% sodium 
chloride. The microdilutions trays were inoculated 
with an inoculum of 10’ cfu/mL and incubated at 
35°C for 24 hours. Following the NCCLS criteria, the 
organism was considered resistant to oxacillin if the 
MIC was greater than 2 pg/mL. 
The molecular epidemiology of the MRSA out- 
break in Hospital de Bellvitge has been recently 
described.“’ For the current study, similar tech- 
niques (pulsed-field gel electrophoresis and mecil 
polymorphism analysis) were applied to assess the 
identity among colonizing and bacteremic strains of 
MRSA and MSSA. 
Statistical Analysis 
For purpose of data analysis, patients with MRSA 
carriage and with prior ICU MSSA nasal colonization 
(MRSA recolonization) were considered only as 
MRSA carriage. Patient characteristics and several 
other clinically relevant variables present before na- 
sal carriage were analyzed in MRSA carriers and 
compared with MSSA carriers. 
Rates of nosocomial S awe-us bacteremia were de- 
termined in noncarriers, MRSA carriers, and MSSA 
carriers. Risk factors for nosocomial S aureu.s bac- 
teremia among nasal carriers were analyzed using 
univariate and multivariate analyses. The (X-square 
or Fisher’s exact tests were used to compare pro- 
portions and the Student t-test to compare means. 
Cumulative Kaplan-Meier plots were constructed 
with day of nasal S aureus carriage as the starting 
point and the first episode of bacteremia as the end 
point, and curves were compared by means of the 
log rank test. To determine the independent predic- 
tors of bacteremia, we performed a Cox propor- 
tional-hazards regression analysis, including the fol- 
lowing covariates: type of nasal carriage (MRSA 
versus MSSA) , SAPS at time of colonization, antibi- 
otic therapy from day of colonization to bacteremia 
(in cases) or discharge (in controls), and three or 
more intravascular catheters in place. 
A P value less than 0.05 was considered statisti- 
cally signillcant, and all reported P values were two- 
sided. The statistical analysis was performed using 
SPSS/PC and BMDP statistical packages. 
RESULTS 
Nasal Staphylococcal Carriage 
From March 1991 to April 1992, 488 patients ad- 
mitted to our ICU for more than 48 hours were in- 
cludcd in the study. Of them, 147 (30.1%) were nasal 
staphylococcal carriers; 63 (12.9%) were M:RSA, and 
84 (17.2%) MSSA carriers. Sixteen (25%) of the 
MRSA carriers had prior MSSA colonization detected 
during the ICU stay, but on the contrary, no case 
turned to MSSA after MRSA colonization. Among 
MSSA nasal carriers, 77 (92%) were positive for 
MSSA at admission to ICU, whereas the other 7 pa- 
tients developed MSSA nasal colonization after the 
first week of ICU stay. Among MRSA carriers, 56 
(89%) developed nasal carriage after the fist week 
of ICU stay; patients with positive MRSA nasal swab 
culture at admission were colonized in other areas 
before ICU admittance (four patients), or had early 
ICU-acquired MRSA nasal colonization (three pa- 
tients). Fifty-six (88.8%) of 63 MRSA carriers had 
two or more positive nasal swab cultures during ICU 
stay and were considered patients with stable nasal 
colonization, one ( 1.6%) patient had a negative nasal 
swab control after an MRSA positive culture and was 
considered transient colonization, and six (9.5%) pa- 
tients had a positive MRSA nasal swab culture with- 
out further controls because of ICU discharge within 
a week of positive MRSA cultures. Among MSSA pa- 
tients, 44 (52.3%) had stable colonization with two 
or more positive nasal swab cultures, 12 (14.2%) had 
transient colonization, and 28 (33.3%) had a positive 
nasal swab culture without subsequent controls be- 
cause of ICU discharge within a week. 
A comparison of clinical and epidemiological fea- 
tures between MRSA and MSSA carriers is shown in 
Table I. Patients with MRSA carriage, compared 
with MSSA carriers, had higher SAPS at ICU admis- 
sion, longer length of ICU stay, surgery, and greater 
intravascular device use, mechanical ventil.ation, an- 
tibiotic therapy, tracheostomy, and pressure ulcers. 
In addition, length of nasal carriage was longer in 
MRSA than in MSSA cases. However, no differences 
were observed in the mortality rate during ICU stay 
between both groups (28.5% for MRSA and 23.8% for 
MSSA carriers; P = nonsignilicant) . Besides clinical 
findings, characterization of MRSA isolates by chro- 
mosomal DNA fingerprinting showed a dominant 
clone during the study period, whereas great molec- 
ular variability was observed among MSSA isolates 
(Figure 1). 
Nosocomial S aureus Bacteremia 
Nosocomial S a.ureus bacteremia was diagnosed 
in 38 (7.7%) of the 488 patients included in the study; 
32 (84%) of these patients had prior nasal staphylo- 
coccal carriage, whereas the other six patients ( 16%) 
had negative nasal swabs performed prior to bac- 
teremia. Among bacteremic patients with prior neg- 
ative nasal swab cultures, three (one MSS4 and two 
MRSA) remained free of nasal staphylococcal car- 
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TABLE I 
Comparison of Clinical and Epidemiological Features between MRSA and MSSA Nasal Carriers 
(Univariate Analysis) 
MRSA MSSA 
(n = 63) (n = 84) P Value 
Age (yrs) (mean t SD) 47.2 (1~20.7) 42.6 (k18.1) 0.166 
Sex: male/female (%) 46 (73)/l 7 (27) 61 (73)/23 (27) 0.957 
Severity of underlying disease: 
McCabe, Group 1 (%I 42 (66.7) 61 (72.6) 0.435 
SAPS (?SD) 11.5 b3.5) 10.2 k3.3) 0.045 
Primary diagnosis: 
COPD (%) 8 (12.7) 4 (4.8) 0.086 
Polytrauma (%I 30 (47.6) 38 (45.2) 0.774 
Malignancy (%) 8 (12.7) 8 (9.5) 0.540 
Liver disease 2 (3.2) 12 (14.5) 0.021 
Prior to staphylococcal colonization 
ICU stay: mean days (?SD) 15.0 (t10.5) 2.7 (~4.5) <O.Ol 
Surgery (%I 38 (60.3) 31 (36.9) <O.Ol 
23 Intravascular catheters 39 (61.9) 30 (35.7) <O.Ol 
Mechanical ventilation (%I 59 (93.7) 69 (82.1) 0.039 
Urinary catheter (%) 61 (96.8) 81 (96.4) 0.895 
Tracheostomy (%) 11 (17.5) 2 (2.4) <O.Ol 
Pressure ulcers (%I 6 (9.5) 0 0.013 
Antibiotic Rx (%) 60 (95.2) 10 (11.9) <O.Ol 
Source of bacteremia 
Bacteremia (%) 24 (38.1) 8 (9.5) <O.Ol 
Intravascular catheter (%I 14 (58.3) 5 (62.5) 
Unknown (%I 9 (37.5) 2 (25) 
Secondary source l(4.1) l(12.5) 
Outcome 
Overall KU mortality (%I 18 (28.5) 20 (23.8) 0.643 
riage during their ICU stay, while the other three pa- 
tients with MRSA bacteremia had nasal staphylococ- 
cal carriage detected after MRSA bacteremia. All 
bacteremic patients with nasal staphylococcal car- 
riage had the same susceptibility pattern in nasal 
swabs as in blood cultures; in addition, pairs of iso- 
lates had clonal similarity by molecular typing (Fig- 
ure 1) . Twenty-four (38%) of 63 MRSA carriers, eight 
(9.5%) of 84 MSSA carriers, and six (1.7%) of 341 
noncarriers developed nosocomial S aureus bac- 
teremia during the study period (P <O.OOl). Mean 
days (2SD) from nasal staphylococcal colonization 
to bacteremia were 11.1 (2 13.4) for MRSA carriers 
compared with 6.1 (k5.2) for MSSA carriers (P = 
0.14). Primary bacteremia was the most common 
source of bacteremia among MRSA and MSSA car- 
riers (Table I), as well as in noncarriers (six of six 
episodes). Patients with MRSA colonization and 
with initial MSSA colonization had similar clinical 
and epidemiological characteristics as well as simi- 
lar risk of developing S aureus bacteremia as pa- 
tients with MRSA carriage but without initial MSSA 
colonization: six of 16 (37.5%) MSSA/MRSA carriers, 
compared with 18 of 47 (38.3%) MRSA carriers. 
Overall mortality from bacteremia was eight of 24 
(33.3%) for MRSA cases and three of eight (37.5%) 
for MSSA cases (P = NS). 
Nosocomial S aureus Bacteremia Risk Factors 
among Nasal Carriers 
The univariate analysis comparing 321 bacteremic 
nasal carriers with 115 nonbacteremic nasal carriers 
is shown in Table II. There were no significant dif- 
ferences between the two groups in terms of age, 
SAPS at ICU admission, McCabe classification, and 
surgery. Significant differences were found in the fol- 
lowing variables for bacteremic versus nonbacter- 
emit carriers: SAPS measured on the dlay of staph- 
ylococcal colonization ( 11.1 rt 3.1 versus 9.9 f 3.5, 
respectively), rates of nasal MRSA carriage (75% 
versus 33.9%), use of antibiotic therapy after staph- 
ylococcal colonization (65.6% versus 92.2%)) and 
use of m3 intravascular catheters (62.5% versus 
43.5%). Figure 2 shows the Kaplan-Meier estimated 
probability of developing S a,ureus bacteremia after 
nasal colonization among both groups of carriers. 
The probability of developing S aureus bacteremia 
was higher in MRSA than in MSSA carriers. On the 
contrary, the probability of developing S aureus bac- 
teremia was lower in patients who received antibi- 
otic therapy than in those who did not (Figure 3). 
A detailed analysis of antibiotic therapy after staph- 
ylococcal colonization among bacteremic and non- 
bacteremic patients is shown in Table III. The ad- 
ministration of vancomycin among MRSA carriers 
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Figure 1. Smal restriction patterns generated from chromosomal 
DNA of S aureus isolates after PFGE. A. The methicillin-resistant S 
aureus dominant clone is shown, excepting lanes 6 and 9, containing 
PFGE subtypes from the epidemic strain, and lane 12, with a repre- 
sentative from a distinct clone (lanes 1 and 15, molecular weight 
markers). B. The methicillin-susceptible S aureus chromosomal vari- 
ety is shown on lanes 2-14. Isolates from the same patient were 
compared side by side; lanes 2,6,8, 11, and 13 contain nasal swabs 
from five patients included in the study; lanes 3, 7, 9, 12, and 14 
contain the methicillin-susceptible S aureus isolated from blood cul- 
tures in the same five patients (lanes 1 and 15, molecular weight 
markers). 
and the administration of betalactams with activity 
against methicillin-susceptible strains among MSSA 
carriers was associated with a significantly lower 
risk of bacteremia. 
After adjustment for severity of illness measured 
by SAPS (day of staphylococcal colonization) and 
the presence of r3 intravascular catheters, the rel- 
ative risks for S aureus bacteremia were 3.9 (95% 
confidence interval [CI], 1.6-9.8; P = 0.002) for 
MRSA carriers compared with MSSA carriers and 
0.04 (95% CI, 0.01-0.1; P +O.OOl) for patients who 
had been receiving antibiotics compared with those 
without antibiotics. 
DISCUSSION 
The epidemiology of nasal staphylococcal carriage 
in ICU patients, as well as its subsequent clinical 
consequences, are still poorly understood because 
few detailed investigations have been carried out in 
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this setting. Our study, performed during an ex- 
tended MRSA outbreak, documents the association 
between nasal S aureus colonization and develop- 
ment of bacteremia. 
It has been reported that up to 25% of patients 
admitted to hospitals will become nasal staphylo- 
coccal carriers, often with prevalent hospital 
strains” ; this figure may be higher for some pop- 
ulations such as diabetic patients, HIV patients, 
and patients on chronic hemodialysis, ranging 
from 40% to 60%.13,21-23 In ICU patients, rates of 
carriage may vary from the 30% found in this study 
to 33-41% observed in other recent re.ports.z”‘25 
Our results showed that MSSA carriage was pre- 
dominantly community acquired and more preva- 
lent than MRSA carriage. Thirteen percent of our 
patients were colonized by the epidemic MRSA 
strain. Molecular epidemiology of the outbreak”’ 
revealed that the majority of MRSA cases were due 
to a single clone that appeared at the beginning of 
the outbreak, colonizing patients and sanitary per- 
sonnel and spreading rapidly throughout, the hos- 
pital. 
It is noteworthy that 25% of MRSA carriers were 
patients with prior MSSA nasal colonization, sug- 
gesting that some individuals are more prone to col- 
onization than others. This group of patients was in- 
cluded in the study because they had similar clinical 
and epidemiological characteristics than those with 
MRSA carriage alone. 
Studies comparing both methicillin-sensitive and 
methicillin-resistant strains had shown no differ- 
ences in their ability to adhere to nasal epithelial 
cells.26 It is possible that the selective pressure ex- 
erted by some antibiotic therapies may facilitate re- 
colonization by resistant strains. l4 
Host conditions favoring MRSA colonization ob- 
served in our study did not differ from those re- 
ported in other significant outbreaks,5,27-31 such as 
older age, length of ICU stay, multiple antibiotic ther- 
apy, intravascular devices, mechanical ventilation, 
tracheostomy, and pressure ulcers. Beside these fac- 
tors, MRSA carriers had significantly hig:her SAPS 
than did MSSA carriers, revealing poorer clinical 
condition on admission. However, the ICU mortality 
was similar between MRSA and MSSA carriers, sug- 
gesting that these differences had little clinical sig- 
nificance. 
In patients on hemodialysis, several studies have 
emphasized the risk of bacteremia among nasal 
staphylococcal carriers and, more importantly, some 
have showed the eradication of such carriage to be 
highly effective in the reduction of staphylococcal 
infection rates.“-l3 Recently, a French multicenter 
study performed in five polyvalent ICUs with a high 
endemic rate of MRSA colonization det’ected the 
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TABLE II 
Risk Factors for Nosocomial S aureus Bacteremia among Nasal Carriers Admitted to ICU 
Bacteremia No Bacteremia 
(n = 32) (n = 115) P Value 
Mean age (yrs) (zSD) 45.7 (i-21.6) 44.2 (~18.7) 0.724 
Sex: male/female (%) 20 (62.5)/12 (37.5) 87 (76)/28 (24) 0.139 
Severity of the underlying diseases 
McCabe Group 1 (%) 24 (75) 79 (68.7) 0.491 
SAPS at ICU admission (?SD) 11.3 (i-2.9) 10.6 (k3.5) 0.341 
SAPS at day of colonization (?SD) 11.1 b3.1) 9.9 (23.5) 0.064 
Surgery (%) 16 (501 53 (46.1) 0.847 
Primary diagnosis: 
COPD (%) 4 (12.5) 8 (6.9) 0.294 
Polytrauma (%I 14 (43.8) 54 (47) 0.747 
Malignancy (%I 6 (18.8) 10 (8.7)’ 0.195 
Liver disease 2 (6.3) 12 (10.4) 0.735 
Heart Disease (%) 1 14 (12.1) 0.192 
Type of carriage 
MRSA colonization (%I 24 (75) 39 (33.9) <O.Ol 
ICU stay’ d (?SD) 9.7 (k12.1) 15.1 k14) 0.036 
Antibiotic Therapy+ 
Antibiotic therapy (%) 21 (65.6) 106 (92.2) <O.Ol 
Beta-lactams (%I 16 (50) 97 (84.3) <O.Ol 
Aminoglycosides (%) 8 (25) 18 (15.7) 0.220 
Glycopeptide (%I 4 (12.5) 57 (12.5) <O.Ol 
Quinolones 1%) 10 (31.3) 23 (20) 0.177 
Other antibiotics (%) 8 (25) 27 (23.5) 0.858 
Devices in place’ 
Mechanical ventilation (%I 28 (87.5) 100 (87) 0.935 
Urinary catheter (%I 31 (96.9) 111 (96.5) 0.922 
Intravascular catheterization: 
~3 I.V. catheters (%I 20 (62.5) 50 (43.5) 0.056 
* From day of detection of nasal staphylococcal carriage to discharge (or bacteremia for bacteremic patients). 
L Patients with one or more antibiotics from day of detectlon of nasal staphylococcal carriage to discharge (or bacteremla for 
bacteremic pattents). 
A Cox proportional hazard regression analysis (see methods) showed: MRSA colonization (RR, 3.9; 95%; Cl, 1.6-9.8) and 
antibiotic therapy (RR, 0.04; 95% Cl, 0.01-0.1) as the independent risk factors for S aureus bacteremla. 
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Figure 2. Kaplan-Meier estimated probability of developing S aureus 
bacteremia after nasal colonization among both groups of carriers. 
presence of prior nasal colonization among patients 
with subsequent MRSA infections.“5 
In our series, episodes of S aureus bacteremia oc- 
curred almost exclusively in patients with previous 
nasal colonization, and most were due to definite or 
probable infections of intravascular catheters. Over- 
all, these observations suggest that the majority of 
episodes of S aweus bacteremia are due to the pa- 
tient’s own flora, either community acquired or no- 
socomial acquired throughout cross transmission 
during hospitalization. 
A recent study by Muder et al”” reported a higher 
rate of staphylococcal infections among MRSA car- 
riers than among MSSA carriers, suggesting that 
methicillin-resistant strains could be more virulent; 
however, differences in infection rates could be as- 
cribed to underlying diseases. Similarly, we observed 
a significantly higher number of S aweus bacteremia 
among MRSA carriers. Therefore, we performed a 
proportional-hazards regression analysis, which 
identified MRSA carriage as an independent risk fac- 
tor for bacteremia. It should be taken into account 
that, while the majority of variables regarding signif- 
icant contributing factors for bacteremia are easily 
defined, others such as intravascular catheterization 
(which comprises days, number, and types of intra- 
vascular catheters) are not; in fact, the days of intra- 
vascular catheterization variable is similar to the 
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Figure 3. Kaplan-Meier estimated probability of developing S aureus 
bacteremia in patients receiving antibiotic therapy and in patients not 
given antibiotic therapy. 
TABLE III 
Antibiotic Therapy during Staphylococcal Carriage 
No 
Bacteremia Bacteremia 
MRSA Carriers (n = 24) (n = 39) P Value 
Antibiotic therapy (%I 17 (70.8) 38 (97.4) <O.Ol 
Beta-lactams* 1%) 13 (54.2) 32 (82.1) 0.017 
Beta-lactams+ (%I 10/20 (50) 9/14 (64.3) 0.409 
Aminoglycosides (%I 7 (29.2) 7 (17.9) 0.298 
Glycopeptide (%) 4 (16.7) 25 (64.1) to.01 
Quinolones (%I 10 (41.7) 13 (33.3) 0.504 
Other antibiotics (%) 8 (33.3) 21 (53.8) 0.112 
No 
Bacteremia Bacteremia 
MSSA Carriers (n = 8) (n = 76) P Value 
Antibiotic therapy 1%) 4 (50) 68 (89.5) <O.Ol 
Beta-lactams (%) 3 (37.5) 65 (85.5) <O.Ol 
Aminoglycosides (%I l(12.5) 11 (14.5) 0.870 
Glycopeptide (%) 0 (0) 32 (42.1) 0.051 
Quinolones (%) 0 (0) 10 (13.2) 0.603 
Other antibiotics (%I 0 (0) 6 (7.9) 0.917 
’ All patients with betalactam therapy; 26 of them were on simultaneous 
vancomycin therapy. 
+ Patients with betalactam therapy but without simultaneous vancomycin 
therapy. 
days of ICU admission variable. Another limitation 
of our study is that it is not known whether mea- 
surement of SAPS is an adequate score for evaluat- 
ing clinical condition defined as a risk factor for 
bloodstream infection in ICU patients. 
Whether different infection rates were due to dif- 
ferences in intrinsic virulent properties among staph- 
ylococcal strains or to differences in clinical condi- 
tions of carriers, or to both, is difficult to assess.33-3i 
In addition, some in vitro studies have failed to dem- 
onstrate different virulence factors, such as adher- 
ence, survival, enterotoxin, hemolysins, and co- 
agulase production between MSSA and MRSA 
strains.““m40 
Another tiding of the study was that the admin- 
istration of antibiotic therapy during staphylococcal 
NOSOCOMIAL S AUREUS BACTEREMIA/PUJOL ET AL 
colonization may diminish the probability of devel- 
oping bacteremia. This was especially evident for pa- 
tients receiving glycopeptide antibiotics. However, it 
should be emphasized that the administration of pro- 
phylactic antibiotics for preventing nosocoNmial bac- 
teremia is not currently an accepted clin:ical prac- 
tice. 
Several conclusions can be drawn from our ex- 
perience: among ICU patients, nasal carriers of S au- 
reus are at higher risk for S aureus bacteremia than 
are noncarriers; therefore, attempts to eradicate car- 
rier state may be clinically useful. During outbreaks, 
patients with MRSA carriage are at very high risk of 
developing bacteremia. Besides the reinforcement of 
other control measures, improving care of intravas- 
cular catheters could reduce the incidence of bac- 
teremic episodes. Further studies are needed to eval- 
uate results derived from eradication of nasal 
carriage in ICU patients. 
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